The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
Abstract
Barium ferrite nanoparticles (BaFeNPs) were investigated as vehicles for 223Ra radionuclide in targeted α-therapy. BaFe nanoparticles were labeled using a hydrothermal Ba2+ cations replacement by 223Ra with yield reaching 61.3 ± 1.8%. Radiolabeled nanoparticles were functionalized with 3-phosphonopropionic acid (CEPA) linker followed by covalent conjugation to trastuzumab (Herceptin®). Thermogravimetric analysis and radiometric method with the use of [131I]-labeled trastuzumab revealed that on average 19–21 molecules of trastuzumab are attached to the surface of one BaFe–CEPA nanoparticle. The hydrodynamic diameter of BaFe–CEPA–trastuzumab conjugate is 99.9 ± 3.0 nm in water and increases to 218.3 ± 3.7 nm in PBS buffer, and the zeta potential varies from +27.2 ± 0.7 mV in water to −8.8 ± 0.7 in PBS buffer. The [223Ra]BaFe–CEPA–trastuzumab radiobioconjugate almost quantitatively retained 223Ra (>98%) and about 96% of 211Bi and 94% of 211Pb over 30 days. The obtained radiobioconjugate exhibited high affinity, cell internalization and cytotoxicity towards the human ovarian adenocarcinoma SKOV-3 cells overexpressing HER2 receptor. Confocal studies indicated that [223Ra]BaFe–CEPA–trastuzumab was located in peri-nuclear space. High cytotoxicity of the [223Ra]BaFe–CEPA–trastuzumab bioconjugate was confirmed by radiotoxicity studies on SKOV-3 cell monolayers and 3D-spheroids. In addition, the magnetic properties of the radiobioconjugate should allow for its use in guide drug delivery driven by magnetic field gradient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shannon, R. D. (1976) · Acta Crystallographica Section A · doi:10.1107/s0567739476001551 · Cited by 66,145
Research works printed but not linked: 56
- Baidoo, 2013, Molecular pathways: Targeted alpha-particle radiation therapy, Clin. Cancer Res., 19, 530, 10.1158/1078-0432.CCR-12-0298 · DOI · Paper page
- Bandekar, 2014, Anti–prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer, J. Nucl. Med., 55, 107, 10.2967/jnumed.113.125476 · DOI
- Ferrier, 2019, Radiochemical aspects of alpha emitting radionuclides for medical application, Radiochim. Acta, 107, 1065, 10.1515/ract-2019-0005 · DOI
- Makvandi, 2018, Alpha-emitters and targeted alpha therapy in oncology: From basic science to clinical investigations, Target. Oncol., 13, 189, 10.1007/s11523-018-0550-9 · DOI · Paper page
- Morgenstern, 2018, An overview of targeted alpha therapy with 225actinium and 213bismuth, Curr. Radiopharm., 11, 200, 10.2174/1874471011666180502104524 · DOI · Paper page
- Kratochwil, 2018, Targeted alpha-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-plot analysis suggests efficacy regarding duration of tumor control, J. Nucl. Med., 59, 795, 10.2967/jnumed.117.203539 · DOI · Paper page
- Sathekge, 2019, Ac-225-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: A pilot study, Eur. J. Nucl. Med. Mol. Imaging, 46, 129, 10.1007/s00259-018-4167-0 · DOI · Paper page
- Colletti, 2013, New treatment option: 223Ra chloride, the first approved unsealed α-emitting radiopharmaceutical, Clin. Nucl. Med., 38, 724, 10.1097/RLU.0b013e3182a2dd53 · doi:10.1097/rlu.0b013e3182a2dd53
- Chang, C.A. (1996). Selectivity of macrocyclic aminocarboxylates for alkaline-earth metal ions and stability of their complexes. J. Chem. Soc. Dalton Trans., 2347–2350. · doi:10.1039/dt9960002347
- Henriksen, 2002, Evaluation of potential chelating agents for radium, Appl. Radiat. Isot., 56, 667, 10.1016/S0969-8043(01)00282-2 · DOI
- Gott, 2019, A 224Ra-labeled polyoxopalladate as a putative radiopharmaceutical, Chem. Commun., 55, 7631, 10.1039/C9CC02587A · DOI
- Aboul, 2020, MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer, J. Nucl. Med., 61, 587
- Henriksen, 2004, Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides, Nucl. Med. Biol., 31, 441, 10.1016/j.nucmedbio.2003.11.004 · DOI
- Jonasdottir, 2006, First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent, Anticancer Res., 26, 2841
- Reissig, 2019, Facile preparation of radium-doped, functionalized nanoparticles as carriers for targeted alpha therapy, Inorg. Chem. Front., 6, 1341, 10.1039/C9QI00208A · DOI
- Reissig, 2020, Sub-10 nm Radiolabeled barium sulfate nanoparticles as carriers for theranostic applications and targeted alpha therapy, ChemistryOpen, 9, 1, 10.1002/open.202000201 · DOI
- Severin, 2019, Dynamics of sorption–desorption of 223Ra therapeutic α-emitter on granulated hydroxyapatite, Radiochemistry, 61, 339, 10.1134/S1066362219030093 · doi:10.1134/s1066362219030093
- Vasiliev, 2017, Hydroxyapatite particles as carriers for 223Ra, J. Radioanal. Nucl. Chem., 311, 1503, 10.1007/s10967-016-5007-y · doi:10.1007/s10967-016-5007-y
- Suchankova, 2020, Study of 223Ra uptake mechanism on hydroxyapatite and titanium dioxide nanoparticles as a function of pH, RSC Adv., 10, 3659, 10.1039/C9RA08953E · DOI
- Kozempel, 2015, Prospective carriers of 223Ra for targeted alpha therapy, J. Radioanal. Nucl. Chem., 304, 443, 10.1007/s10967-014-3615-y · DOI
- Piotrowska, 2013, Functionalized NaA nanozeolites labeled with 224,225Ra for targeted alpha therapy, J. Nanopart. Res., 15, 2082, 10.1007/s11051-013-2082-7 · DOI
- Piotrowska, 2017, Nanozeolite bioconjugates labeled with Ra-223 for targeted alpha therapy, Nucl. Med. Biol., 47, 10, 10.1016/j.nucmedbio.2016.11.005 · DOI
- Czerwińska, M., Fracasso, G., Pruszyński, M., Bilewicz, A., Kruszewski, M., Majkowska-Pilip, A., and Lankoff, A. (2020). Design and Evaluation of 223Ra-Labeled and Anti-PSMA Targeted NaA Nanozeolites for Prostate Cancer Therapy–Part, I. Materials, 13. · DOI
- McLaughlin, 2014, LnPO4 nanoparticles doped with Ac-225 and sequestered daughters for targeted alpha therapy, Cancer Biother. Radiopharm., 29, 34
- Woodward, 2011, LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides, Bioconjug. Chem., 22, 766, 10.1021/bc100574f · DOI
- McLaughlin, 2013, Gold-coated lanthanide phosphate nanoparticles for an 225Ac in vivo alpha generator, Radiochim. Acta, 101, 595, 10.1524/ract.2013.2066 · doi:10.1524/ract.2013.2066
- McLaughlin, M.F., Woodward, J., Boll, R.A., Wall, J.S., Rondinone, A.J., Kennel, S.J., Mirzadeh, S., and Robertson, D. (2013). Gold coated lanthanide phosphate nanoparticles for targeted alpha generator radiotherapy. PLoS ONE, 8. · DOI
- Dame, 2019, Gadolinium vanadate nanocrystals as carriers of α-emitters (Ac-225, Th-227) and contrast agents, J. Appl. Phys., 125, 214901, 10.1063/1.5096880 · doi:10.1063/1.5096880
- Rojas, 2015, Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for 223Ra and 225Ra for targeted alpha therapy, Nucl. Med. Biol., 42, 614, 10.1016/j.nucmedbio.2015.03.007 · DOI
- Fu, 2003, Nanopatterning of “hard” magnetic nanostructures via dip-pen nanolithography and a sol-based ink, Nano Lett., 3, 757, 10.1021/nl034172g · DOI
- Kappiyoor, 2010, The effects of magnetic nanoparticle properties on magnetic fluid hyperthermia, J. Appl. Phys., 108, 094702, 10.1063/1.3500337 · DOI
- Belous, A.G. (2014, January 26–30). Synthesis and properties of ferromagnetic nanostructures and their possible use in medicine and microwave engineering. Proceedings of the International Conference on Oxide Materials for Electronic Engineering—Fabrication, Properties and Applications (OMEE-2014), Lviv, Ukraine. · DOI
- Jones, 2005, Randomized trial of hyperthermia and radiation for superficial tumors, J. Clin. Oncol., 23, 3079, 10.1200/JCO.2005.05.520 · DOI · Paper page
- Song, 2005, Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment, Int. J. Hyperth., 21, 761, 10.1080/02656730500204487 · DOI · Paper page
- Maeda, 2014, Dual in vivo photoacoustic and fluorescence imaging of HER2 expression in breast tumors for diagnosis, margin assessment, and surgical guidance, Mol. Imaging, 13, 1
- Drofenik, 2011, The hydrothermal synthesis of super-paramagnetic barium hexaferrite particles, Mater. Chem. Phys., 127, 415, 10.1016/j.matchemphys.2011.02.037 · doi:10.1016/j.matchemphys.2011.02.037
- Cędrowska, E., Pruszyński, M., Gawęda, W., Żuk, M., Krysiński, P., Bruchertseifer, F., Morgenstern, A., Karageorgou, M.-A., Bouziotis, P., and Bilewicz, A. (2020). Trastuzumab conjugated superparamagnetic iron oxide nanoparticles labeled with 225Ac as a perspective tool for combined radioimmunotherapy and magnetic hyperthermia of HER2-positive breast cancer. Molecules, 25. · DOI
- Dziawer, Ł., Majkowska-Pilip, A., Gaweł, D., Godlewska, M., Pruszyński, M., Jastrzębski, J., Wąs, B., and Bilewicz, A. (2019). Trastuzumab-modified gold nanoparticles labeled with 211At as a prospective tool for local treatment of HER2-positive breast cancer. Nanomaterials, 9. · DOI
- Jacobo, 2003, Evolution of the magnetic properties during the thermal treatment of barium hexaferrite precursors obtained by coprecipitation from barium ferrate (VI) solutions, J. Magn. Magn. Mater., 260, 37, 10.1016/S0304-8853(01)00924-6 · doi:10.1016/s0304-8853(01)00924-6
- Zahari, 2016, Structural and magnetic properties of hexagonal barium ferrite synthesized through the sol-gel combustion route, AIP Conf. Proc., 1787, 070002, 10.1063/1.4968136 · doi:10.1063/1.4968136
- Yang, 2005, Preparation of rodlike barium ferrite particles by inverse microemulsion method, Chin. J. Inorg. Chem., 21, 607
- Sankaranarayanan, 1996, Mechanism of the formation of nanoscale M-type barium hexaferrite in the citrate precursor method, J. Magn. Magn. Mater., 153, 337, 10.1016/0304-8853(95)00537-4 · DOI
- Mishra, 2004, Studies on characterization, microstructures and magnetic properties of nano-size barium hexa-ferrite prepared through a hydrothermal precipitation-calcination route, Mater. Chem. Phys., 86, 132, 10.1016/j.matchemphys.2004.02.017 · doi:10.1016/j.matchemphys.2004.02.017
- Liu, 1999, Improving the magnetic properties of hydrothermally synthesized barium ferrite, J. Magn. Magn. Mater., 195, 452, 10.1016/S0304-8853(99)00123-7 · doi:10.1016/s0304-8853(99)00123-7
- Che, 2003, Soft magnetic nanoparticles of BaFe12O19 fabricated under mild conditions, J. Phys. Condens. Matter., 15, L335, 10.1088/0953-8984/15/22/101 · doi:10.1088/0953-8984/15/22/101
- Mokhodoeva, 2016, Study of 223Ra uptake mechanism by Fe3O4 nanoparticles: Towards new prospective theranostic SPIONs, J. Nanopart. Res., 18, 301, 10.1007/s11051-016-3615-7 · DOI
- Wolterbeek, 2015, A critical review of alpha radionuclide therapy—How to deal with recoiling daughters?, Pharmaceuticals, 8, 321, 10.3390/ph8020321 · DOI · Paper page
- Mohammadi, 2016, Chromium (VI) ions adsorption onto barium hexaferrite magnetic nano-adsorbent, Adv. Mater. Lett., 77, 579, 10.5185/amlett.2016.6394 · doi:10.5185/amlett.2016.6394
- Patel, 2012, Arsenic removal by magnetic nanocrystalline barium hexaferrite, J. Nanopart. Res., 14, 881, 10.1007/s11051-012-0881-x · doi:10.1007/s11051-012-0881-x
- Holzwarth, 2018, A random walk approach to estimate the confinement of α-particle emitters in nanoparticles for targeted radionuclide therapy, EJNMMI Radiopharm. Chem., 3, 9, 10.1186/s41181-018-0042-3 · DOI
- Majkowska-Pilip, A., Gawęda, W., Żelechowska-Matysiak, K., Wawrowicz, K., and Bilewicz, A. (2020). Nanoparticles in targeted alpha therapy. Nanomaterials, 10. · DOI
- Pruszynski, 2018, Evaluation of an anti-HER2 nanobody labeled with 225 Ac for targeted α-particle therapy of cancer, Mol. Pharm., 15, 1457, 10.1021/acs.molpharmaceut.7b00985 · DOI
- Pruszynski, 2013, Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody, Nucl. Med. Biol., 40, 52, 10.1016/j.nucmedbio.2012.08.008 · DOI
- Cai, 2017, Local radiation treatment of HER2-positive breast cancer using trastuzumab-modified gold nanoparticles labeled with 177Lu, Pharm. Res., 34, 579, 10.1007/s11095-016-2082-2 · DOI
- Cai, 2016, In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection, Nucl. Med. Biol., 43, 818, 10.1016/j.nucmedbio.2016.08.009 · DOI
- Ballangrud, 2004, Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: Efficacy versus HER2/neu expression, Clin. Cancer Res., 13, 4489, 10.1158/1078-0432.CCR-03-0800 · DOI
Metadata
- Authors
- Gawęda, W., Pruszyński, M., Cędrowska, E., Rodak, M., Majkowska-Pilip, A., Gaweł, D., Bruchertseifer, F., Morgenstern, A., & Bilewicz, A.
- Venue
- Nanomaterials
- Publisher
- MDPI AG
- Published
- 2020-10-20
- Volume
- 10
- Issue
- 10
- Pages
- 2067
- ISSN
- 2079-4991
- Cited by
- 41
- References
- 1
- Language
- en
- Funders
- National Science Center, Poland (2015/17/N/ST4/03943, 2016/21/B/ST4/02133)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy. https://app.cochat.ai/papers/10.3390/nano10102067
- The paper
- Gawęda, W., Pruszyński, M., Cędrowska, E., Rodak, M., Majkowska-Pilip, A., Gaweł, D., Bruchertseifer, F., Morgenstern, A., & Bilewicz, A. (2020). Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy. Nanomaterials. https://doi.org/10.3390/nano10102067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.